An 18-month double-blind treatment of multiple sclerosis with low dose oral methotrexate showed it to be well tolerated and suggested effectiveness in exacerbating-remitting MS but not in the exacerbating progressive and chronic progressive stages.
CiteULike
Connotea
Delicious
Digg
Facebook
Google+
Mendeley
Reddit
Technorati
TwitterCiteULikeConnoteaDeliciousDiggFacebookGoogle+MendeleyRedditTechnoratiTwitter
Free sample
This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of
JNNP.
View free sample issue >>
Free archive
The full back archive is now available for JNNP. Institutional subscribers may access the entire archive as part of their
subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have
free access to all articles published before 2006, back to volume 1 issue 1.
Register to access the free archive >>
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
Online ISSN 1468-330X
Copyright © 2012 by the BMJ Publishing Group Ltd. All rights reserved.
